Quantcast

Worried About Johnson & Johnson’s Valuation? Consider This Crazy Undervalued, 4.2% Yielding Pharmaceutical Stock Instead

Posted On March 30, 2017 5:55 pm
By:

Johnson & Johnson is one of the best dividend growth stocks you can own. However, at today’s valuation investors might want to consider waiting for a pullback. In the meantime here’s a high-yielding alternative pharma stock, one that is 40% undervalued, and could be one of the best performer of the coming years.

Continue Reading Here

About author

Dividend Sensei
Dividend Sensei

I’m an Army veteran and former energy dividend writer for The Motley Fool. I currently write for both Seeking Alpha, Simply Safe Dividends, Investorplace.com, and TheStreet.com.

My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams, and enrich their lives. With 20 years of investing experience, I’ve learned what works and more importantly, what doesn’t, when it comes to building long-term wealth and income streams. I’m currently on an epic quest to build a broadly diversified, high-quality, high-yield dividend growth portfolio that:

1. Pays a 4% to 5% yield
2. Offers 9% to 10% annual dividend growth
3. Pays dividends AT LEAST on a weekly, but preferably, daily basis

Related Articles